Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365918 | 0.83 | KCNH2 (0.42) | SPHK1KCNH2 | |
| SCHEMBL3591166 | 0.69 | SPHK1 (0.46) | MAPK14MCHR1SPHK2SPHK1KCNH2 | |
| SCHEMBL4601498 | 0.66 | MCHR1 (0.39) | MAPK14MCHR1KCNH2 | |
| SCHEMBL4489978 | 0.66 | MAPK14 (0.68) | MAPK14MCHR1 | |
| SCHEMBL1522893 | 0.64 | MAPK14 (0.65) | MAPK14MCHR1KCNH2 | |
| SCHEMBL1040149 | 0.64 | MAPK14 (0.68) | MAPK14MCHR1KCNH2 | |
| SCHEMBL4045555 | 0.63 | MAPK14 (0.72) | MAPK14MCHR1 | |
| Trifluoroacetic Acid SCHEMBL4470437 | 0.63 | MAPK14 (0.48) | MAPK14MCHR1KCNH2 | |
| SCHEMBL4045768 | 0.62 | MCHR1 (0.59) | MAPK14MCHR1 | |
| SCHEMBL2177074 | 0.62 | MAPK14 (1.00) | MAPK14MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | MAPK14 1736/4885MCHR1 220/4885SPHK2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.